Moleculin reports 37% blinded remission rate in AML trial interim data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
July 31, 2026 8:10 AM EDTPrior venetoclax failure a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part A
Preliminary blinded CR of 24% and CRc of 37% (n=62), with essentially identical rates among the 30 patients who had failed first-line venetoclax: CR of 23% and CRc of 37% (3X the published salvage remission rates following first-line venetoclax failure of approximately 13%)Enrollment reaches 74 of 90 patients, with final Part A treatment expected in September 2026 and... More